Answers are grounded in this paper and cite their sources.
Severe bronchial asthma is characterized by a complex pathogenesis, the key links of which are inflammation and allergic reactions. A promising method of treating this nosology is considered to be targeted genetically engineered biological therapy aimed at different targets (cytokines, receptor, or other components of cell signaling) of pathogenesis. However, few studies have investigated the efficacy and safety of monoclonal antibody treatment in the elderly. Meanwhile, aging is also characterized by a specific inflammatory background — inflamaging, which can significantly affect the diagnosis and treatment of the disease. The review summarizes the data of the current literature on the criteria for the effectiveness of treatment with targeted therapy drugs, and also considers promising laboratory candidate markers that have the potential to be a predictor of the effectiveness of therapy for severe bronchial asthma among people over 60 years of age.
No takes yet. Share an insight, caveat, or question.
Урал Ринатович Сагинбаев (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: